Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ambrx Biopharma Inc.AMAM · Entity 109604 | Director | June 07, 2023 | June 09, 2023 |
| Eton Pharmaceuticals, Inc.ETON · Entity 4598 | Director | August 28, 2026 | August 31, 2026 |
| FF EAI Robotics Ecosystem Inc.RTTR · Entity 7776 | Director | January 15, 2020 | January 17, 2020 |
| International Stem Cell CORPISCO · Entity 8432 | Director | September 16, 2026 | September 18, 2026 |
| MABVAX THERAPEUTICS HOLDINGS, INC.MBVX · Entity 167746 | Director | April 02, 2018 | April 04, 2018 |
| SEELOS THERAPEUTICS, INC.APRI · Entity 93662 | Director | January 04, 2018 | January 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ambrx Biopharma Inc.
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 85,000 |
Reported balance
After 2023-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 85,000 · Balance 85,000 F1: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven (7) Ordinary Shares of the Issuer. F2: Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven (7) Ordinary Shares of the Issuer.
F2: Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting.
Eton Pharmaceuticals, Inc.
Report date August 28, 2026 · Filed August 31, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,245 |
Last balance in matching sequence
After 2026-08-28 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-08-28 · Exercise / conversion · Acquired 50,000 · Balance 109,745 Row 2 · 2026-08-28 · Sale · Disposed 36,387 · Balance 73,358 F1: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F2: The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price. Row 3 · 2026-08-28 · Sale · Disposed 13,485 · Balance 59,873 F1: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F4: The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price. Row 4 · 2026-08-28 · Sale · Disposed 128 · Balance 59,745 F1: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F5: The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price. Row 5 · 2026-08-28 · Exercise / conversion · Acquired 12,500 · Balance 72,245 |
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.78 · Expires 2032-02-06 | Direct | 0 |
Reported balance
After 2026-08-28 transaction · row 6
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 6 · 2026-08-28 · Exercise / conversion · Disposed 50,000 · Balance 0 F3: The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-07-2022) until fully vested. |
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.31 · Expires 2029-02-19 | Direct | 0 |
Reported balance
After 2026-08-28 transaction · row 7
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 7 · 2026-08-28 · Exercise / conversion · Acquired 12,500 · Balance 0 F6: The shares subject to the option vested in four equal quarterly installments from the date of grant (02-20-2019) until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F2: The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price.
F3: The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-07-2022) until fully vested.
F4: The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price.
F5: The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price.
F6: The shares subject to the option vested in four equal quarterly installments from the date of grant (02-20-2019) until fully vested.
FF EAI Robotics Ecosystem Inc.
Report date January 15, 2020 · Filed January 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.23 · Expires 2030-01-15 | Direct | 12,000 |
Reported balance
After 2020-01-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-15 · Grant · Acquired 12,000 · Balance 12,000 F1: The option vests in twelve (12) equal monthly installments begining on February 15, 2020 with the balance vesting on the 15th day of each calendar month thereafter until vested in full. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve (12) equal monthly installments begining on February 15, 2020 with the balance vesting on the 15th day of each calendar month thereafter until vested in full.
International Stem Cell CORP
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.12 · Expires 2034-06-11 | Direct | 0 |
Reported balance
After 2026-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-16 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: The shares subject to the option fully vested on 06/11/2025 from the date of grant (06-11-2024). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option fully vested on 06/11/2025 from the date of grant (06-11-2024).
MABVAX THERAPEUTICS HOLDINGS, INC.
Report date April 02, 2018 · Filed April 04, 2018 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,063 |
Reported balance
After 2018-04-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-04-02 · Exercise / conversion · Acquired 513 · Balance 23,063 F1: Represents conversion of restricted stock units into common stock upon vesting of 1/3 of such units granted on April 2, 2015. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-04-02 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2018-04-02 · Exercise / conversion · Disposed 513 · Balance 0 F2: Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer. F3: Restricted Stock Units vest over 3 years from April 2, 2015, 1/3 on each anniversary of the date of grant, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Represents conversion of restricted stock units into common stock upon vesting of 1/3 of such units granted on April 2, 2015.
F2: Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer.
F3: Restricted Stock Units vest over 3 years from April 2, 2015, 1/3 on each anniversary of the date of grant, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date
SEELOS THERAPEUTICS, INC.
Report date January 04, 2018 · Filed January 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2028-01-04 | Direct | 35,000 |
Reported balance
After 2018-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-04 · Grant · Acquired 35,000 · Balance 35,000 F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer. F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of Issuer, as an annual stock option grant for his service as a director of the Issuer.
F2: The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 4, 2018, so that such options are fully vested on January 4, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ambrx Biopharma, Inc.
Report date March 07, 2024 · Filed March 07, 2024
Section 16 reporting ended · disclosed 2024-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-07 · Disposition to issuer · Disposed 12,142 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2032-02-02 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F5: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest in thirty-six (36) equal monthly installments following February 2, 2022. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.96 · Expires 2032-07-07 | Direct | 0 |
Reported balance
After 2024-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-07 · Disposition to issuer · Disposed 15,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7: These Company Options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J.
F2: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock").
F3: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting.
F4: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU.
F5: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest in thirty-six (36) equal monthly installments following February 2, 2022.
F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.
F7: These Company Options are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 00:46 UTC | International Stem Cell CORP ISCO · Entity 8432 | Disposition to issuerStock Options · Derivative | 30,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001683168-26-007223 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to the option fully vested on 06/11/2025 from the date of grant (06-11-2024). Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:12 UTC | International Stem Cell CORP ISCO · Entity 8432 | SaleCommon Stock | 32,802 | $0.32 | $10,496.64 |
DisclosureSEC source: 0001683168-26-007164 · ownership.xml · nonDerivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Through family Trust dated 4/21/2000 Disclosed balance after: 0 Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 20:51 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 50,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001437749-26-029196 · rdgdoc.xml · derivative · entry 5 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-07-2022) until fully vested. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 20:51 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 128 | $61.77 | $7,906.56 |
DisclosureSEC source: 0001437749-26-029196 · rdgdoc.xml · nonDerivative · entry 4 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,745 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F5 · price: The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 20:51 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 13,485 | $60.21 | $811,931.85 |
DisclosureSEC source: 0001437749-26-029196 · rdgdoc.xml · nonDerivative · entry 3 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,873 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F4 · price: The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 20:51 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 36,387 | $58.64 | $2,133,733.68 |
DisclosureSEC source: 0001437749-26-029196 · rdgdoc.xml · nonDerivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,358 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F2 · price: The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price. Read SEC document |
| August 28, 2026 Filed Aug 28, 2026 20:51 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 50,000 | $3.78 | $189,000.00 |
DisclosureSEC source: 0001437749-26-029196 · rdgdoc.xml · nonDerivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:06 UTC Amendment | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 12,500 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001437749-26-029308 · rdgdoc.xml · derivative · entry 7 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2029-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option vested in four equal quarterly installments from the date of grant (02-20-2019) until fully vested. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:06 UTC Amendment | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionEmployee Stock Option · Derivative | 50,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001437749-26-029308 · rdgdoc.xml · derivative · entry 6 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2032-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-07-2022) until fully vested. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:06 UTC Amendment | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 12,500 | $7.31 | $91,375.00 |
DisclosureSEC source: 0001437749-26-029308 · rdgdoc.xml · nonDerivative · entry 5 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:06 UTC Amendment | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 128 | $61.77 | $7,906.56 |
DisclosureSEC source: 0001437749-26-029308 · rdgdoc.xml · nonDerivative · entry 4 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,745 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F5 · price: The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:06 UTC Amendment | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 13,485 | $60.21 | $811,931.85 |
DisclosureSEC source: 0001437749-26-029308 · rdgdoc.xml · nonDerivative · entry 3 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,873 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F4 · price: The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:06 UTC Amendment | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | SaleCommon Stock | 36,387 | $58.64 | $2,133,733.68 |
DisclosureSEC source: 0001437749-26-029308 · rdgdoc.xml · nonDerivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,358 F1 · price: The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. F2 · price: The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price. Read SEC document |
| August 28, 2026 Filed Aug 31, 2026 20:06 UTC Amendment | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | Exercise / conversionCommon Stock | 50,000 | $3.78 | $189,000.00 |
DisclosureSEC source: 0001437749-26-029308 · rdgdoc.xml · nonDerivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:57 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantCommon Stock · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-025700 · rdgdoc.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.exercise_date: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. F1 · derivative.expiration_date: On July 31, 2026, the reporting person was granted 10,000 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range. Read SEC document |
| June 11, 2026 Filed Jun 24, 2026 00:30 UTC | International Stem Cell CORP ISCO · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 182,584 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001683168-26-005073 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,584 Underlying: Common Stock · 182,584 shares Expires 2036-06-11 F2 · derivative.exercise_date: The shares underlying such option shall vest in equal quarterly increments through June 11, 2027, with the first increment vesting on September 11, 2026. Read SEC document |
| June 11, 2026 Filed Jun 24, 2026 00:30 UTC | International Stem Cell CORP ISCO · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001683168-26-005073 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying such option shall vest on the earlier of (a) June 11, 2027, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:06 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantRestricted Stock Units · Derivative | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-001294 · rdgdoc.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,253 Underlying: Common Stock · 7,757 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in one annual installment beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. F3 · derivative.expiration_date: The restricted stock units vest in one annual installment beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 23:06 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,196 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001437749-26-001294 · rdgdoc.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,496 Underlying: Common Stock · 12,196 shares Expires 2036-01-11 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 12, 2027. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 12:18 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 532,786 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001683168-25-004620 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 532,786 Underlying: Common Stock · 532,786 shares Expires 2035-06-17 F2 · derivative.exercise_date: The shares underlying such option shall vest in equal quarterly increments through June 17, 2026, with the first increment vesting on September 17, 2025. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 12:18 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001683168-25-004620 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-06-17 F1 · derivative.exercise_date: The shares underlying such option shall vest on the earlier of (a) June 17, 2026, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant. Read SEC document |
| January 03, 2025 Filed Jan 6, 2025 21:18 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001437749-25-000459 · rdgdoc.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-01-02 F1 · derivative.exercise_date: The shares subject to the option shall vest equally on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on January 3, 2026. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:03 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 361,111 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001683168-24-004176 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 361,111 Underlying: Common Stock · 361,111 shares Expires 2034-06-11 F2 · derivative.exercise_date: Options shall vest in four equal quarterly increments, beginning September 11, 2024. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:03 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001683168-24-004176 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: Options shall vest on the earlier of (i) June 11, 2025 or (ii) the date of the 2025 Annual Meeting of Stockholders. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:34 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 15,000 | Not disclosed Strike: $1.96 | Not disclosed |
DisclosureSEC source: 0000950170-24-028171 · ownership.xml · derivative · entry 3 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2032-07-07 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F7 · derivative.exercise_date: These Company Options are fully vested and exercisable. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:34 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerOption to Purchase Common Stock · Derivative | 30,000 | Not disclosed Strike: $1.96 | Not disclosed |
DisclosureSEC source: 0000950170-24-028171 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2032-02-02 F6 · price: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of Company Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration. F5 · derivative.exercise_date: The Company Common Stock subject to the options to purchase shares of Company Common Stock (each, a "Company Option") vest in thirty-six (36) equal monthly installments following February 2, 2022. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 17:34 UTC | Ambrx Biopharma, Inc. AMAM · Entity 93373 | Disposition to issuerRestricted Stock Units · Derivative | 12,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-028171 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,142 shares Expires not disclosed F1 · derivative.exercise_price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 5, 2024, among the Issuer, Johnson & Johnson ("J&J"), and Charm Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of March 7, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. F2 · derivative.exercise_price: Each of these restricted stock units ("RSUs") represents a contingent right to receive one share of common stock of the Issuer ("Company Common Stock"). F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration, without interest and less any applicable withholding taxes, in respect of each such RSU. F3 · derivative.exercise_date: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting. F3 · derivative.expiration_date: These RSUs vest as follows: on the earlier of (i) the one year anniversary of the grant date of June 7, 2023, and (ii) the day before the next annual general meeting. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:16 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 30,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001437749-24-004359 · rdgdoc.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,555 Underlying: Common Stock · 30,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 13, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:23 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 445,205 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001683168-23-004226 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 445,205 Underlying: Common Stock · 445,205 shares Expires 2033-06-14 F2 · derivative.exercise_date: Options vest in four equal quarterly increments, beginning 09/14/2023. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:23 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.14 | $0.00 |
DisclosureSEC source: 0001683168-23-004226 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: Options vest fully at the earlier of (i) 06/14/2024 or (ii) the date of the 2024 Annual Meeting of Stockholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:05 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantOrdinary Shares | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015152 · doc4.xml · nonDerivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · security: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven (7) Ordinary Shares of the Issuer. F2 · shares: Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting. Read SEC document |
| March 03, 2023 Filed Mar 3, 2023 21:10 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option(Right to buy) · Derivative | 25,000 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001493152-23-006674 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,555 Underlying: Common Stock · 25,000 shares Expires 2033-02-19 F1 · date: Option was approved by the Compensation Committee of the Board of Directors as of February 20, 2023 and approved by the full Board of Directors on March 3, 2023. F2 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 20, 2024. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:14 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantStock Option (right to buy) · Derivative | 105,000 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-005790 · doc4.xml · derivative · entry 4 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 105,000 shares Expires 2032-07-07 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F4 · derivative.exercise_date: The Ordinary Shares subject to the option will vest on the earlier of (i) July 8, 2023, or (ii) the day immediately prior to the date of the next Annual Grant Date as defined in the Company's Non-Employee Director Compensation Policy. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:14 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | Disposition to issuerStock Option (right to buy) · Derivative | 105,000 | Not disclosed Strike: $0.43 | Not disclosed |
DisclosureSEC source: 0001209191-23-005790 · doc4.xml · derivative · entry 3 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 105,000 shares Expires 2032-07-07 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F4 · derivative.exercise_date: The Ordinary Shares subject to the option will vest on the earlier of (i) July 8, 2023, or (ii) the day immediately prior to the date of the next Annual Grant Date as defined in the Company's Non-Employee Director Compensation Policy. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:14 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | GrantStock Option (right to buy) · Derivative | 210,000 | Not disclosed Strike: $0.28 | Not disclosed |
DisclosureSEC source: 0001209191-23-005790 · doc4.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Ordinary Shares · 210,000 shares Expires 2032-02-01 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F1 · derivative.exercise_date: The Ordinary Shares subject to the option vest in thirty-six equal monthly installments following February 2, 2022. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 18:14 UTC | Ambrx Biopharma Inc. AMAM · Entity 109604 | Disposition to issuerStock Option (right to buy) · Derivative | 210,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0001209191-23-005790 · doc4.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 210,000 shares Expires 2032-02-01 F3 · price: The option held by the reporting person was amended to reduce the exercise price. F1 · derivative.exercise_date: The Ordinary Shares subject to the option vest in thirty-six equal monthly installments following February 2, 2022. F2 · derivative.underlying: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 21:01 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001683168-22-004287 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-06-09 F2 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest fully at the earlier of (i) 06/09/2023 or (ii) the date of the 2023 Annual Meeting of Stockholders. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 21:01 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 139,264 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001683168-22-004287 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,264 Underlying: Common Stock · 139,264 shares Expires 2032-06-09 F1 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest in four equal quarterly increments, beginning 9/09/2022. Read SEC document |
| February 07, 2022 Filed Feb 28, 2022 21:36 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option(Right to buy) · Derivative | 50,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001493152-22-005620 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,555 Underlying: Common Stock · 50,000 shares Expires 2032-02-07 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7, 2023. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 18:11 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001683168-21-002469 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-09 F2 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest fully at the earlier of (i) June 09, 2022 or (ii) the date of the 2022 Annual Meeting of Stockholders, with vesting accelerated for all shares in the event of a change in control. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 18:11 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 183,481 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001683168-21-002469 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,481 Underlying: Common Stock · 183,481 shares Expires 2031-06-09 F1 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest in four equal quarterly increments, beginning 9/09/2021. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:15 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option(Right to buy) · Derivative | 19,655 | $0.00 Strike: $8.61 | $0.00 |
DisclosureSEC source: 0001493152-21-010523 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,555 Underlying: Common Stock · 19,655 shares Expires 2031-05-03 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:43 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001683168-20-002055 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-23 F2 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest fully at the earlier of (i) June 23, 2021 or (ii) the date of the 2021 Annual Meeting of Stockholders, with vesting accelerated for all shares in the event of a change in control. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 20:43 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 46,428 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001683168-20-002055 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,428 Underlying: Common Stock · 46,428 shares Expires 2030-06-23 F1 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest in four equal quarterly increments, with first increment vesting on 9/23/2020. Read SEC document |
| June 23, 2020 Filed Jun 26, 2020 22:04 UTC Amendment | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 92,857 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001683168-20-002089 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,857 Underlying: Common Stock · 92,857 shares Expires 2030-06-23 F1 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest in four equal quarterly increments, with first increment vesting on 9/23/2020. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 20:54 UTC | Eton Pharmaceuticals, Inc. ETON · Entity 4598 | GrantStock Option (Right to buy) · Derivative | 27,400 | $0.00 Strike: $3.58 | $0.00 |
DisclosureSEC source: 0001493152-20-004056 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,400 Underlying: Common Stock · 27,400 shares Expires 2030-03-11 F1 · derivative.exercise_date: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on March 12, 2021. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 23:06 UTC | FF EAI Robotics Ecosystem Inc. RTTR · Entity 7776 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $0.23 | $0.00 |
DisclosureSEC source: 0001382963-20-000010 · edgar.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-01-15 F1 · derivative.exercise_date: The option vests in twelve (12) equal monthly installments begining on February 15, 2020 with the balance vesting on the 15th day of each calendar month thereafter until vested in full. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:46 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001683168-19-001799 · ownership.xml · derivative · entry 2 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2019-06-03 F2 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest fully at the earlier of (i) June 3, 2020 or (ii) the date of the 2020 Annual Meeting of Stockholders, with vesting accelerated for all shares in the event of a change in control. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:46 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | GrantStock Option (Right to Buy) · Derivative | 71,982 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001683168-19-001799 · ownership.xml · derivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,982 Underlying: Common Stock · 71,982 shares Expires 2019-06-03 F1 · derivative.exercise_date: Stock option granted as part of compensation for non-employee directors. Options vest in four equal quarterly increments, with first increment vesting on 9/03/2019. Read SEC document |
| April 18, 2019 Filed Apr 22, 2019 18:12 UTC | International Stem Cell CORP ISCO.OB · Entity 8432 | SaleCommon Stock | 1,350 | $1.25 | $1,680.75 |
DisclosureSEC source: 0001683168-19-001143 · ownership.xml · nonDerivative · entry 1 MAIER PAUL V · CIK 0001182615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,710 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.